# Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma

> **NCT00003616** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00003616
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-10-22
- **Primary completion:** 2002-05-17
- **Final completion:** 2005-12-20
- **Target enrollment:** — (—)
- **Last updated:** 2018-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003616, "Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00003616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*